新型氟喹诺酮类药物CP-99,219对革兰氏阳性菌临床分离株的体外活性
In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria.
作者信息
Eliopoulos G M, Klimm K, Eliopoulos C T, Ferraro M J, Moellering R C
机构信息
Department of Medicine, New England Deaconess Hospital, Boston, Massachusetts 02215.
出版信息
Antimicrob Agents Chemother. 1993 Feb;37(2):366-70. doi: 10.1128/AAC.37.2.366.
Abstract
The in vitro activity of the fluoroquinolone CP-99,219 against gram-positive bacteria was compared with those of five other antimicrobial agents. Against ciprofloxacin-susceptible staphylococci and against streptococci, MICs were < or = 0.12 and < or = 0.5 microgram/ml, respectively. CP-99,219 was also more active than ciprofloxacin against ciprofloxacin-resistant staphylococci, most enterococci, Leuconostoc spp., and lactobacilli.
摘要
将氟喹诺酮类药物CP-99,219对革兰氏阳性菌的体外活性与其他五种抗菌剂进行了比较。对于对环丙沙星敏感的葡萄球菌和链球菌，其最小抑菌浓度（MIC）分别≤0.12微克/毫升和≤0.5微克/毫升。CP-99,219对耐环丙沙星的葡萄球菌、大多数肠球菌、明串珠菌属和乳杆菌的活性也高于环丙沙星。
相似文献
1
In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria.新型氟喹诺酮类药物CP-99,219对革兰氏阳性菌临床分离株的体外活性
Antimicrob Agents Chemother. 1993 Feb;37(2):366-70. doi: 10.1128/AAC.37.2.366.
2
In vitro activity of trovafloxacin (CP 99,219), a new fluoroquinolone against hospital isolates.新型氟喹诺酮类药物曲伐沙星（CP 99,219）对医院分离菌的体外活性
Chemotherapy. 1999 Jan-Feb;45(1):22-7. doi: 10.1159/000007161.
3
Comparative in vitro activities of trovafloxacin (CP-99,219) against 445 gram-positive isolates from patients with endocarditis and those with other bloodstream infections.曲伐沙星（CP-99,219）对445株来自心内膜炎患者和其他血流感染患者的革兰氏阳性分离株的体外活性比较
Antimicrob Agents Chemother. 1997 May;41(5):1146-9. doi: 10.1128/AAC.41.5.1146.
4
In vitro activity of sparfloxacin, ciprofloxacin, ofloxacin, and other antibiotics against bloodstream isolates of gram-positive cocci.司帕沙星、环丙沙星、氧氟沙星及其他抗生素对革兰氏阳性球菌血流感染分离株的体外活性
Diagn Microbiol Infect Dis. 1993 Jul;17(1):85-91. doi: 10.1016/0732-8893(93)90077-k.
5
In vitro activity of the new fluoroquinolone CP-99,219.新型氟喹诺酮CP-99,219的体外活性
Antimicrob Agents Chemother. 1994 Nov;38(11):2615-22. doi: 10.1128/AAC.38.11.2615.
6
Antibacterial activity of trovafloxacin against nosocomial Gram-positive and Gram-negative isolates.曲伐沙星对医院内革兰氏阳性和革兰氏阴性分离株的抗菌活性。
J Antimicrob Chemother. 1997 Jun;39 Suppl B:29-34. doi: 10.1093/jac/39.suppl_2.29.
7
Comparative in-vitro activity of the new fluoroquinolone trovafloxacin (CP-99,219) against gram-positive cocci.新型氟喹诺酮曲伐沙星（CP-99,219）对革兰氏阳性球菌的体外活性比较
J Antimicrob Chemother. 1996 May;37(5):1011-6. doi: 10.1093/jac/37.5.1011.
8
In vitro antibacterial activity of trovafloxacin and five other fluoroquinolones.曲伐沙星及其他五种氟喹诺酮类药物的体外抗菌活性
Chemotherapy. 1998 Mar-Apr;44(2):85-93. doi: 10.1159/000007097.
9
Comparative in-vitro activities of trovafloxacin, ciproflaxacin, ofloxacin, and broad-spectrum beta-lactams against aerobe blood culture isolates.曲伐沙星、环丙沙星、氧氟沙星及广谱β-内酰胺类药物对需氧血培养分离菌株的体外活性比较
Zentralbl Bakteriol. 1998 Dec;288(4):509-18. doi: 10.1016/s0934-8840(98)80070-4.
10
The in-vitro activity of trovafloxacin, a new fluoroquinolone, against Gram-positive bacteria.新型氟喹诺酮类药物曲伐沙星对革兰氏阳性菌的体外活性。
J Antimicrob Chemother. 1997 Jun;39 Suppl B:57-62. doi: 10.1093/jac/39.suppl_2.57.
引用本文的文献
1
Effect of ethanol on fluoroquinolone efficacy in a rat model of pneumococcal pneumonia.乙醇对肺炎球菌肺炎大鼠模型中氟喹诺酮疗效的影响。
Antimicrob Agents Chemother. 2006 Jan;50(1):210-9. doi: 10.1128/AAC.50.1.210-219.2006.
2
Successful trovafloxacin prophylaxis against experimental streptococcal aortic valve endocarditis.曲伐沙星成功预防实验性链球菌性主动脉瓣心内膜炎。
Antimicrob Agents Chemother. 2000 Sep;44(9):2564-6. doi: 10.1128/AAC.44.9.2564-2566.2000.
3
Trovafloxacin concentrations in airway fluids of patients with severe community-acquired pneumonia.严重社区获得性肺炎患者气道分泌物中的曲伐沙星浓度。
Antimicrob Agents Chemother. 2000 Jan;44(1):178-80. doi: 10.1128/AAC.44.1.178-180.2000.
4
Activity of newer fluoroquinolones in vitro against gram-positive bacteria.新型氟喹诺酮类药物对革兰氏阳性菌的体外活性。
Drugs. 1999;58 Suppl 2:23-8. doi: 10.2165/00003495-199958002-00005.
5
Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.曲伐沙星与其他氟喹诺酮类药物对金黄色葡萄球菌纯化的拓扑异构酶以及gyrA和grlA突变体的活性比较。
Antimicrob Agents Chemother. 1999 Aug;43(8):1845-55. doi: 10.1128/AAC.43.8.1845.
6
In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone.新型去-F(6)-喹诺酮T-3811ME的体外和体内抗菌活性
Antimicrob Agents Chemother. 1999 May;43(5):1077-84. doi: 10.1128/AAC.43.5.1077.
7
Trovafloxacin in combination with vancomycin against penicillin-resistant pneumococci in the rabbit meningitis model.曲伐沙星联合万古霉素治疗兔脑膜炎模型中耐青霉素肺炎球菌的研究
Antimicrob Agents Chemother. 1999 Apr;43(4):963-5. doi: 10.1128/AAC.43.4.963.
8
In vitro activity of quinupristin/dalfopristin and newer quinolones combined with gentamicin against resistant isolates of Enterococcus faecalis and Enterococcus faecium.奎奴普丁/达福普汀及新型喹诺酮类药物与庆大霉素联合应用对粪肠球菌和屎肠球菌耐药菌株的体外活性
Eur J Clin Microbiol Infect Dis. 1998 Sep;17(9):657-61. doi: 10.1007/BF01708351.
9
Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia.曲伐沙星与大剂量阿莫西林（每日三次，每次1g）治疗社区获得性细菌性肺炎的比较
Eur J Clin Microbiol Infect Dis. 1998 Jun;17(6):447-53. doi: 10.1007/BF01691581.
10
Bacteriological activity of trovafloxacin, a new quinolone, against respiratory tract pathogens.新型喹诺酮类药物曲伐沙星对呼吸道病原体的细菌学活性。
Eur J Clin Microbiol Infect Dis. 1998 Jun;17(6):405-12. doi: 10.1007/BF01691573.
本文引用的文献
1
In-vitro activity of Sch 29482 in comparison with other oral antibiotics.Sch 29482与其他口服抗生素相比的体外活性。
J Antimicrob Chemother. 1982 Feb;9 Suppl C:143-52. doi: 10.1093/jac/9.suppl_c.143.
2
Transferable beta-lactamase. A new mechanism for in vitro penicillin resistance in Streptococcus faecalis.可转移的β-内酰胺酶。粪肠球菌体外青霉素耐药的一种新机制。
J Clin Invest. 1983 Sep;72(3):1168-71. doi: 10.1172/JCI111042.
3
Comparative in vitro activity of WIN 57273, a new fluoroquinolone antimicrobial agent.新型氟喹诺酮抗菌剂WIN 57273的体外活性比较
Antimicrob Agents Chemother. 1990 Jun;34(6):1154-9. doi: 10.1128/AAC.34.6.1154.
4
Rapid dissemination of beta-lactamase-producing, aminoglycoside-resistant Enterococcus faecalis among patients and staff on an infant-toddler surgical ward.产β-内酰胺酶、耐氨基糖苷类的粪肠球菌在婴幼儿外科病房的患者和医护人员中迅速传播。
N Engl J Med. 1990 Dec 27;323(26):1814-8. doi: 10.1056/NEJM199012273232606.
5
Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates.对三种新型喹诺酮类药物（司帕沙星、CI-960和PD 131,628）的体外活性与环丙沙星对5252株临床分离细菌的活性进行多中心评估。
Antimicrob Agents Chemother. 1991 Apr;35(4):764-6. doi: 10.1128/AAC.35.4.764.
6
Comparison of Enterococcus raffinosus with Enterococcus avium on the basis of penicillin susceptibility, penicillin-binding protein analysis, and high-level aminoglycoside resistance.基于青霉素敏感性、青霉素结合蛋白分析及高水平氨基糖苷类耐药性对棉子糖肠球菌和鸟肠球菌的比较
Antimicrob Agents Chemother. 1991 Jul;35(7):1408-12. doi: 10.1128/AAC.35.7.1408.
7
Comparative in vitro activity of PD 127391, a new fluoroquinolone agent, against susceptible and resistant clinical isolates of gram-positive cocci.新型氟喹诺酮类药物PD 127391对革兰氏阳性球菌敏感及耐药临床分离株的体外活性比较
Antimicrob Agents Chemother. 1992 Jun;36(6):1325-8. doi: 10.1128/AAC.36.6.1325.
Zotero 插件